Cargando…
LGG-21. Durability of response to targeted therapies in pediatric low-grade gliomas: A multi-institution retrospective review
Background: The discovery of the driving oncogenic alterations in pediatric low-grade gliomas (pLGGs) has shifted our focus towards management with targeted therapies, especially in relapsing or progressive disease. Limited data is available on the durability of response to targeted therapy in pLGGs...
Autores principales: | Cantor, Evan, Chaturvedi, Sneha, Reiners, Stephanie, Ogle, Andrea, Meyer, Ashley, Cluster, Andrew, Brossier, Nicole M, Dholaria, Hetal, Govender, Dinisha, Nagabushan, Sumanth, Schwartz, Johnathan, Abdelbaki, Mohamed S, Navalkele, Pournima, Shatara, Margaret |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164842/ http://dx.doi.org/10.1093/neuonc/noac079.335 |
Ejemplares similares
-
LGG-02. Cardiac toxicity in patients receiving single-agent MEK inhibition
por: Cantor, Evan, et al.
Publicado: (2022) -
LGG-39. Ascites in a medullary and leptomeningeal ganglioglioma patient following cisplatin treatment necessitating cessation of therapy and conversion to VA shunt
por: Cantor, Evan, et al.
Publicado: (2022) -
LGG-38. Dose-dependent seizure control for an NF1 patient treated via MEK-inhibition for optic pathway glioma
por: Cantor, Evan, et al.
Publicado: (2022) -
LGG-28. Rapid symptomatic improvement for a patient treated with BRAF inhibition for BRAFV600E mutated ganglioglioma
por: Cantor, Evan, et al.
Publicado: (2022) -
LGG-53. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG)
por: Mueller, Sabine, et al.
Publicado: (2020)